UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S152

2016

Volltextzugriff (PDF)

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

European journal of cancer (1990), 2014-05, Vol.50, p.e27-e27

2014

Volltextzugriff (PDF)

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S11-S11

2013

Volltextzugriff (PDF)

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S254-S255

2023

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S389-S390

2024

Volltextzugriff (PDF)

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

Annals of oncology, 2022-11, Vol.33, p.S1591

2022

Volltextzugriff (PDF)

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Annals of oncology, 2022-11, Vol.33, p.S1564-S1564

2022

Volltextzugriff (PDF)

Treatment of NSCLC Patients with EGFR Mutation

Annals of oncology, 2012-10, Vol.23, p.xi29

Yang, J.C.-H.

2012

Volltextzugriff (PDF)

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

Annals of oncology, 2023-10, Vol.34, p.S848-S849

2023

Volltextzugriff (PDF)

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S246-S247

2024

Volltextzugriff (PDF)

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

Annals of oncology, 2023-11, Vol.34, p.S1669-S1670

2023

Volltextzugriff (PDF)

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S798-S798

2021

Volltextzugriff (PDF)

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Annals of oncology, 2019-11, Vol.30, p.ix181

2019

Volltextzugriff (PDF)

1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations

Annals of oncology, 2024-09, Vol.35, p.S867-S867

2024

Volltextzugriff (PDF)

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S463

2022

Volltextzugriff (PDF)

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S350

2022

Volltextzugriff (PDF)

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1684-S1685

2023

Volltextzugriff (PDF)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1661

2023

Volltextzugriff (PDF)

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

Annals of oncology, 2020-11, Vol.31, p.S1396-S1396

2020

Volltextzugriff (PDF)

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

Annals of oncology, 2022-11, Vol.33, p.S1565-S1565

2022

Volltextzugriff (PDF)

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Annals of oncology, 2023-10, Vol.34, p.S776-S776

2023

Volltextzugriff (PDF)

29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S57

2023

Volltextzugriff (PDF)

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S360

2023

Volltextzugriff (PDF)

OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S52

2023

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(133)

Publikationsform

Artikel
(133)

Sprache

Englisch
(133)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(10)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Treatment of NSCLC Patients with EGFR Mutation

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study

Aktive Filter

Suchergebnisse filtern